FT671是有效、非共价的、选择性的 USP7 抑制剂，IC₅₀ 值为 52 nM，与USP7催化域结合的 K_d 值为65 nM。

FT671 is a potent, non-covalent and selective USP7 inhibitor with an IC 50 of 52 nM and binds to the USP7 catalytic domain with a K d of 65 nM.

Solid

IC50: 52 nM (USP7)
Kd: 65 nM (USP7)

FT671 increases p53 protein levels in HCT116 or bone osteosarcoma (U2OS) cell lines, leading to induction of p53 target genes including BBC3 (which encodes PUMA), CDKN1A (p21), RPS27L (S27L) and MDM2. FT671 leads to the degradation of N-Myc and upregulation of p53 in the neuroblastoma cell line IMR-32. FT671 also stabilizes p53 in the MM.1S multiple myeloma cell line, which correlates with increased MDM2 ubiquitination and leads to expression of p53 target genes. has not independently confirmed the accuracy of these methods. They are for reference only.

FT671 (100 mg/kg and 200 mg/kg, Oral gavage, daily) treatment in mice leads to a significant dose-dependent inhibition of tumor growth. And FT671 is well-torelated even at high doses. has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model:

Room temperature in continental US; may vary elsewhere.

Powder -20°C 3 years；4°C 2 years

[1]. Turnbull AP, et al. Molecular basis of USP7 inhibition by selective small-molecule inhibitors. Nature. 2017 Oct 26;550(7677):481-486.

In Vitro: DMSO : 50 mg/mL (93.72 mM; Need ultrasonic)配制储备液